Connect Biopharma (CNTB) director granted 3,738 fully vested shares as fees

Rhea-AI Filing Summary

Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.

Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 3,738 Ordinary Shares of the company on June 30, 2026. These fully vested shares were issued at no cash cost to him in lieu of a portion of his 2026 annual board cash retainers for service during the second quarter of 2026.

After this equity award, he directly holds 86,554 Ordinary Shares of Connect Biopharma. The number of shares granted was determined by dividing the elected cash amount by the average closing price of the company’s ordinary shares over the 30 days preceding June 30, 2026, rounded down to the nearest whole share.

Insider Trade Summary

Net Buyer: 3,738 shares

Net Buy 1 txn

Insider Xanthopoulos Kleanthis Gabriel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	3,738	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 86,554 shares (Direct)

Footnotes (1)

1. F1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.

Key Figures

Shares granted: 3,738 Ordinary Shares Post-transaction holdings: 86,554 Ordinary Shares Transaction price per share: $0.0000 per share +1 more

4 metrics

Shares granted 3,738 Ordinary Shares Equity award in lieu of 2026 cash board retainers for Q2 service

Post-transaction holdings 86,554 Ordinary Shares Director’s direct ownership after June 30, 2026 grant

Transaction price per share $0.0000 per share Reported on Form 4 for the compensation share grant

Transaction date June 30, 2026 Grant date for fully vested Ordinary Shares

Key Terms

Non-Employee Director Compensation Program, fully vested shares, board retainers, average closing price

4 terms

Non-Employee Director Compensation Program financial

"In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive..."

fully vested shares financial

"Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation..."

board retainers financial

"in lieu of a portion of cash compensation for his 2026 annual board retainers."

average closing price financial

"calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026..."

The average closing price is the arithmetic mean of a security’s end-of-day prices over a chosen period, found by adding each day’s closing price and dividing by the number of days. It smooths out daily ups and downs to show a typical market value—like averaging daily temperatures to understand a month’s climate—and helps investors spot trends, judge whether a stock is generally rising or falling, and make clearer buy or sell decisions.

FAQ

What insider transaction did CNTB director Xanthopoulos report on this Form 4?

Dr. Kleanthis Gabriel Xanthopoulos reported receiving 3,738 fully vested Ordinary Shares of Connect Biopharma. The shares were an equity award granted as part of his non-employee director compensation, rather than an open-market purchase or sale.

Why did CNTB grant 3,738 shares to its director instead of paying cash?

The director elected to receive fully vested shares in lieu of a portion of cash compensation under Connect Biopharma’s Non-Employee Director Compensation Program. This election applied to his 2026 annual board retainers for service during the second quarter of 2026.

At what price were the 3,738 CNTB shares calculated for the director grant?

The number of shares was calculated by dividing the applicable equity value by the average closing price of Connect Biopharma’s ordinary shares for the 30 days preceding June 30, 2026, then rounding down to the nearest whole share.

How many CNTB shares does director Xanthopoulos own after this transaction?

Following the grant, Dr. Xanthopoulos directly owns 86,554 Ordinary Shares of Connect Biopharma. This figure reflects his updated direct holdings after receiving 3,738 fully vested shares as part of his 2026 non-employee director compensation.

Was the CNTB director’s 3,738-share award an open-market purchase or sale?

No. The 3,738-share award was a grant/award acquisition reported with code A, representing compensation shares in lieu of cash. It was not an open-market buy or sell and involved no transaction price per share in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:27 PM Accepted by SEC EDGAR 07/01/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xanthopoulos Kleanthis Gabriel

(Last) (First) (Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/30/2026		A		3,738(1)	A	$0	86,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)